CervoMed Inc. Price & Performance (CRVO)

Tagworks Pharmaceuticals has received FDA clearance for its Investigational New Drug application, enabling the launch of a Phase 1 trial for TGW101, a targeted cancer therapy. Additionally, the company has appointed Dr. Keith Orford as Chief Medical Officer, signaling a strengthened leadership team as clinical development begins.12

BridgeBio Pharma announced it will report first quarter 2025 financial results and provide updates on its pipeline after markets close on April 29. The company, recognized for its focus on genetic diseases, will host a webcast to discuss performance and ongoing research with investors and analysts.3

NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will participate in a fireside chat at the H.C. Wainwright @ Home event today. CEO Dr. Jonathan Javitt is expected to discuss the company’s strategic direction and ongoing clinical initiatives, offering investors insight into future plans and development priorities.4